by Raynovich Rod | Jan 30, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-4 Mixed stock market in healthcare and biotech but in an overall weak day as FED and CPI looms. IBB down 0.62% to $132 level. Abbvie (ABBV) beats with Revenue of $58.04B an increase of 3.3% but Humira biosimilars weigh on profit forecast ; pipeline and Botox...
by Raynovich Rod | Jul 29, 2014 | 2023 Rayno Tools and Diagnostics Portfolio
Update -2 Aug. 1 Draft Guidance on LDTs Coming from FDA in 60 Days: Tests Must Be Validated More regulation coming means greater development costs and potential time delays for clinical tests in development and currently marketed as LDTs . Presumably LDT tests will be...
by Rod Raynovich | Sep 21, 2010 | 2020-21 Life Science Portfolios, BIOgraph
Sequenom (SQNM) $7, Market Cap $529M, 76M Sh. Outstanding Sequenom presented a financial update and their plans for their T21 trisomy 21 noninvasive pre-natal test for fetal gene and chromosomal abnormalities. The Company plans to launch a CLIA LDT (lab developed...
by Rod Raynovich | Mar 18, 2010 | BIOgraph
Sequenom is finding price support today at $5.75, volume of 4.6M at 1p, after a severe three day downdraft triggered by their earnings release. Net loss for Q4 was $18.4M on Revenues of $10.8M. Cash position is $42M. Some pundits didn’t like the inability of...